Back to search results

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Abroad (travel likely)RecruitingPHASE3

Conditions

Esophageal Cancer · Gastric Cancer (GC) · Gastroesophageal Junction

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Helios CR Inc./RadNet, Cerritos, California, United States

    Contact: Study coordinator (Sabrina Mora) · Sabrina.mora@heliosclinical.com · 562-693-4477
    Contact: Study coordinator (Alexis Velasco) · alexis.velasco@heliosclinical.com
    Contact: Principal Investigator (Omkar Marathe, M.D.)

  • City of Hope National Cancer Center, Duarte, California, United States

    Contact: Study coordinator (Miranda Qian) · lqian@coh.org · (626) 218-3533
    Contact: Principal Investigator (Dani Castillo, M.D.)

  • Hoag Memorial Hospital, Irvine, California, United States

    Contact: Study coordinator (Beth Thomsen) · Beth.thomsen@hoag.org · 949-557-0285
    Contact: Principal Investigator (Gary Ulaner, MD)

  • UCLA, Los Angeles, California, United States

    Contact: Study coordinator (Steven Stokes) · SStokes@mednet.ucla.edu · 310 206-7436
    Contact: Principal Investigator (Mark Girgis, MD)

  • Stanford University, Stanford, California, United States

    Contact: Study coordinator (Kavin Tamizhmani) · ktamizhm@stanford.edu · (650)-497-6046
    Contact: Principal Investigator (Matteo Novello, MD)

  • Moffit Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Jacqueline Guillermo Adams) · Jacqueline.GuillermoAdams@moffitt.org · 813-745-2468
    Contact: Principal Investigator (Ghassan El-Haddad, MD)

  • Indiana University Health University Hospital, Indianapolis, Indiana, United States

    Contact: Study coordinator (Eric Grubbs) · eegrubbs@iu.edu · (317) 274-2584
    Contact: Principal Investigator (Cindy Yuan, MD PhD)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Isabelle Lin) · ilin4@mgh.harvard.edu · 617-643-6837
    Contact: Principal Investigator (Shadi Esfahani, MD)

  • UMass/Shields, Worcester, Massachusetts, United States

    Contact: Study coordinator (Sara Schiller) · Sara.Schiller1@umassmed.edu · 774-548-1090
    Contact: Principal Investigator (Elisa Franquet-Elia, MD)

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Kera Delaney) · delaney.kera@mayo.edu · 507-293-2227
    Contact: Principal Investigator (Ajit H Goenka, MD)

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Study coordinator (Ilda Bander) · Ilda.bander@mountsinai.org · 212-241-0763
    Contact: Principal Investigator (Sampanna Rayamajhi, MD)

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Jordayna Francois) · francoij@mskcc.org · (646)888-6819
    Contact: Principal Investigator (Aria Razmari, MD)

  • Cleveland Clinic, Cleveland, Ohio, United States

    Contact: Study coordinator (Molly Haberkorn) · HABERKS@ccf.org · 216-445-6434
    Contact: Principal Investigator (Nicholas Austin, DO)

  • Kettering, Kettering, Ohio, United States

    Contact: Study coordinator (Kathren Garber) · kathren.garber@ketteringhealth.org · 937-395-8390
    Contact: Principal Investigator (Arif Sheikh, MD)

  • University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Erin Schubert) · Erin.schubert@pennmedicine.upenn.edu · 215-573-6569
    Contact: Principal Investigator (Mark Sellmyer, MD, PhD)
Study leads

  • Sherly Mosessian, Ph.D

    Study Director

    SOFIE

View source on ClinicalTrials.gov(opens in a new tab)